Tag: sodium glucose cotransporter 2 sglt2 inhibitors market share analysis.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size From 2025 to 2034?

The market size of sodium glucose cotransporter 2 (sglt2) inhibitors has demonstrated robust growth in the recent past. The projected expansion indicates an increase from $10.17 billion in 2024 to $10.96 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The significant growth in previous periods may be accounted for by successful early clinical trials, a surge in regulatory approvals, a rise in diagnoses of diabetes, and an increasing demand for novel diabetes therapies.

The market size for sodium glucose cotransporter 2 (sglt2) inhibitors is projected to experience significant growth in the upcoming years, estimated to reach a value of $15.09 billion by 2029, with a compound annual growth rate (CAGR) of 8.3%. This expected growth during the forecast period can be linked to a surge in diabetes cases, an increase in obesity rates, heightened public awareness about diabetes management, and its increasing use in treating heart and kidney diseases. Some of the major forthcoming trends include the incorporation of combination treatments, the use of personalized medicine, advancements in technology, and conventional drug creation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

What Are the Core Growth Drivers Propelling the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Forward?

The sodium glucose cotransporter 2 (SGLT2) inhibitor market is projected to expand due to the escalating occurrence of diabetes. Diabetes is a collection of metabolic disorders identified by excessive sugar levels in the blood caused by defects in insulin production, function, or both. The development of diabetes can be due to various factors including urbanization, stress, environmental pollution, and limited access to medical services. SGLT2 inhibitors, used in the treatment of diabetes, lower blood glucose levels by hindering glucose reabsorption in the kidneys, which results in glucose being excreted in the urine. These inhibitors present cardiovascular and renal advantages, making them an effective solution for managing diabetes and related complications. As an example, in December 2023, as per the Australian Bureau of Statistics, a government agency in Australia, it was reported that in 2022, about 1.3 million people, or 5.3% of Australians, were diagnosed with diabetes with similar rates among males (5.8%) and females (4.9%). The occurrence of diabetes has been on a steady rise, substantially increasing with age, peaking at 18.7% in those aged 75 and beyond. Among the types of diabetes, type 2 is the most prevalent, making up 87.6% of all cases. Additionally, factors like being born overseas, residing in underprivileged areas, and living with a disability are linked with increased diabetes instances. Therefore, the surge in diabetes prevalence is a key growth driver for the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

What Segment Types Define the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Structure?

The sodium glucose cotransporter 2 (sglt2) inhibitorsmarket covered in this report is segmented –

1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat

2) By Route Of Administration: Oral Route; Other Route Of Administration

3) By End User: Hospitals; Homecare Settings; Clinics

Subsegments:

1) By Invokana: Generic Invokana (Canagliflozin); Branded Invokana

2) By Jardiance: Generic Jardiance (Empagliflozin); Branded Jardiance

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin); Branded Farxiga

4) By Suglat: Suglat (Sotagliflozin) For Diabetes; Suglat (Sotagliflozin) For Heart Failure

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theSodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry Evolution?

Leading companies in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are keen on advancing dual inhibitor therapeutic approaches to optimize patient results and regulate blood sugar concentrations. Dual inhibitor therapeutic options are methods that concurrently target two disparate sodium-glucose cotransporters (SGLT1 and SGLT2) to boost efficiency in dealing with conditions like heart failure and diabetes. For example, in May 2023, Lexicon Pharmaceuticals Inc., an American biopharmaceutical enterprise, obtained approval from the Food and Drug Administration (FDA) for sotagliflozin, a medication for heart failure. This pioneer, a dual inhibitor of sodium-glucose cotransporters 1 and 2, is a once-daily tablet configured to minimize cardiovascular death, hospitalizations due to heart failure, and urgent heart failure appointments in adults with heart failure, type 2 diabetes, chronic kidney illness, and other cardiovascular risk factors. Advantages include diminished renal glucose and sodium reabsorption, which results in the reduction of preload and afterload and reduced sympathetic activity.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

What Is the Definition of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Estimated Market Size of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029?#_x000D_

The market size for sodium glucose cotransporter 2 (SGLT2) inhibitors has significantly expanded in the past few years. From being valued at $10.17 billion in 2024, it is projected to escalate to $11.07 billion in 2025, representing a compound annual growth rate (CAGR) of 8.8%. Factors contributing to the previous period’s growth include successful early stage clinical trails, an uptick in regulatory approvals, an increase in the diagnosis of diabetes, and the growing demand for groundbreaking treatments for diabetes._x000D_

_x000D_

#What Growth Rate Is Forecasted for the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market by 2029?#_x000D_

The market size for sodium glucose cotransporter 2 (SGLT2) inhibitors is poised to experience robust expansion in the upcoming years. By 2029, it is projected to reach $15.4 billion, progressing at a compound annual growth rate (CAGR) of 8.6%. Factors contributing to growth in the prediction period include surging incidence of diabetes, escalating rates of obesity, heightened awareness about managing diabetes, and broadening use in treating heart and kidney diseases. The forecast period is expected to witness trends such as the incorporation of combination therapies, personalized medicine tactics, advances in technology, and conventional drug development._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp_x000D_

_x000D_

#Which Key Companies Are Shaping the Future of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?#_x000D_

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd._x000D_

_x000D_

#Which Factors Are Driving Demand in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?#_x000D_

The rising incidence of diabetes is anticipated to drive the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes is a set of metabolic diseases marked by elevated blood sugar, caused by irregularities in insulin secretion, insulin function, or both. Urbanization, stress, environmental contaminants, and limited healthcare accessibility are among the elements contributing to the surge in diabetes cases. Sodium glucose cotransporter 2 (SGLT2) inhibitors, which can decrease blood glucose levels by stopping glucose reabsorption in the kidneys, thereby leading to its removal through urine, are employed to treat diabetes. They also provide cardiovascular and renal benefits, rendering them an effective strategy for diabetes management and its associated complications. For instance, as reported by the Australian Bureau of Statistics in December 2023, around 5.3% of Australians, or nearly 1.3 million individuals, were diagnosed with diabetes in 2022, with similar rates in men (5.8%) and women (4.9%). Diabetes incidence has been steadily on the rise, noticeably increasing with age, and peaks at 18.7% in individuals aged 75 and above. Type 2 diabetes is the most prevalent, making up 87.6% of cases. Aspects such as foreign birth, residency in disadvantaged regions, and disabilities are linked to higher diabetes incidence. As a result, the escalating incidence of diabetes is propelling the sodium glucose cotransporter 2 (SGLT2) inhibitor market’s growth._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp_x000D_

_x000D_

#How Is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segmented by Several Divisions?#_x000D_

The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat_x000D_

2) By Route Of Administration: Oral Route, Other Route Of Administration_x000D_

3) By End User: Hospitals, Homecare Settings, Clinics_x000D_

_x000D_

Subsegments:_x000D_

1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana_x000D_

2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance_x000D_

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga_x000D_

4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure_x000D_

_x000D_

_x000D_

#What are the Emerging Market Trends Driving the Growth of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?#_x000D_

Leading businesses within the sodium glucose cotransporter 2 (SGLT2) inhibitor market are channeling their efforts towards the development of dual inhibitor therapeutic treatments in an effort to enhance patient results and regulate blood sugar levels. These treatments work by simultaneously targeting SGLT1 and SGLT2, two different sodium-glucose cotransporters, to provide more effective management of conditions like diabetes and heart failure. In an illustrative case, Lexicon Pharmaceuticals Inc., a biopharmaceutical company headquartered in the United States, was granted approval in May 2023 by the Food and Drug Administration (FDA) for their heart failure treatment, sotagliflozin. This pioneering dual inhibitor of sodium-glucose cotransporters 1 and 2, comes in a once-daily tablet form and aims to decrease cardiovascular fatalities, hospitalizations due to heart failure, and urgent visits for heart failure in adults having heart failure, type 2 diabetes, chronic kidney disease, along with other cardiovascular risk factors. Its unique feature is the ability to decrease renal glucose and sodium reabsorption, thereby reducing preload and afterload, and curtailing sympathetic activity._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report_x000D_

_x000D_

#Which Regions Are Driving Growth in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?#_x000D_

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the sodium glucose cotransporter 2 (sglt2) inhibitors market, and how is it changing globally?_x000D_

2. Who are the major companies in the sodium glucose cotransporter 2 (sglt2) inhibitors market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the sodium glucose cotransporter 2 (sglt2) inhibitors market right now?_x000D_

4. Which products or customer segments are growing the most in the sodium glucose cotransporter 2 (sglt2) inhibitors market?_x000D_

5. What factors are helping or slowing down the growth of the sodium glucose cotransporter 2 (sglt2) inhibitors market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the sodium glucose cotransporter 2 (sglt2) inhibitors industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market, and What Factors Will Drive It?

The market size of the sodium glucose cotransporter 2 (SGLT2) inhibitors has seen a robust growth in the past few years. The market, which is at $10.17 billion in 2024, is expected to escalate to $11.07 billion in 2025, marking a compound annual growth rate (CAGR) of 8.8%. Positive outcomes from early clinical trials, increasing regulatory authorizations, a surge in the diagnosis rate of diabetes, and the need for innovative diabetes treatments are the key factors that have contributed to the growth during the previous period.

The market for sodium glucose cotransporter 2 (SGLT2) inhibitors is predicted to experience substantial growth in the upcoming years, expanding to $15.4 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This expectant growth during the forecast period is primarily driven by an increase in diabetes cases, a rise in obesity levels, heightened awareness around diabetes management, and broadening uses in the treatment of heart and kidney diseases. Key trends during this period encompass the incorporation of combination therapies, the adoption of personalized medical practices, advancements in technology, and classic drug development approaches.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Which Factors and External Forces Are Driving Demand in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

The sodium glucose cotransporter 2 (SGLT2) inhibitor market is predicted to expand due to the growing incidence of diabetes. Diabetes is a cluster of metabolic diseases marked by elevated blood sugar caused by issues in insulin production, insulin function, or both. The surge in diabetes cases has been linked to elements like urbanization, stress, environmental pollutants and inadequate healthcare access. SGLT2 inhibitors, which are utilized to control diabetes, work by reducing blood glucose levels, inhibiting glucose reuptake in the kidneys resulting in glucose elimination through urine. These inhibitors also provide cardiovascular and kidney advantages, rendering them an important resource for managing diabetes and its related complications. As an example, data from the Australian Bureau of Statistics in December 2023 revealed that 5.3% of Australians, approximately 1.3 million individuals, were identified with diabetes in 2022, with similar levels in males (5.8%) and females (4.9%). The frequency of diabetes has been growing steadily, notably increasing with age, peaking at 18.7% in people aged 75 and up. Type 2 diabetes is the most prevalent, comprising 87.6% of all cases. Factors such as being born overseas, residing in underprivileged areas, and having a disability correlate with higher diabetes rates. As such, the rising incidence of diabetes is fueling the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

How Is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segmented?

The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat

2) By Route Of Administration: Oral Route, Other Route Of Administration

3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:

1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana

2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga

4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

What Are the Fastest-Growing Geographies in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry Dynamics?

Leading firms in the SGLT2 inhibitor market are concentrating their efforts on creating dual inhibitor therapeutic strategies to enhance patient results and control blood sugar levels. Dual inhibitor therapeutic strategies are treatments that concurrently target two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) to increase the effectiveness in handling conditions like heart failure and diabetes. For example, Lexicon Pharmaceuticals Inc., a biopharmaceutical company from the US, received approval from the Food and Drug Administration (FDA) in May 2023 for a heart failure treatment called sotagliflozin. This innovative dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily pill meant to reduce death from cardiovascular issues, hospitalizations due to heart failure, and urgent visits because of heart failure in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risks. The benefits of this treatment include decreased renal glucose and sodium reabsorption, which contribute to reducing preload and afterload and lowering sympathetic activity.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

How Is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Defined and What Are Its Core Parameters?

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the sodium glucose cotransporter 2 (sglt2) inhibitors market grown in recent years?

In recent times, the sodium glucose cotransporter 2 (SGLT2) inhibitors market has experienced robust growth. The market size is projected to escalate from $10.17 billion in 2024 to $11.07 billion in 2025, with a compound annual growth rate (CAGR) of 8.8%. This surge during the historic period has been fueled by successful early clinical trials, a rise in regulatory approvals, a growing rate of diabetes diagnoses, and the need for innovative treatments for diabetes.

How is the sodium glucose cotransporter 2 (sglt2) inhibitors market size expected to evolve during the forecast period?

The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $15.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.

Get your sodium glucose cotransporter 2 (sglt2) inhibitors market report here!

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

Which key drivers are propelling the sodium glucose cotransporter 2 (sglt2) inhibitors market’s growth?

The escalating occurrence of diabetes is anticipated to drive the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes is a collection of metabolic diseases distinguished by elevated blood sugar levels due to problems with insulin secretion, insulin function, or both. The growth in diabetes instances can be linked to factors like urbanization, stress, environmental contaminants, and lack of healthcare access. Sodium glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels in diabetes patients by inhibiting glucose reabsorption in the kidneys, leading to its excretion through urine. These inhibitors also provide cardiac and renal advantages, making them an effective tool for managing diabetes and its associated complications. For example, the Australian Bureau of Statistics reported in December 2023 that in 2022, approximately 1.3 million people, or 5.3% of Australians, were diagnosed with diabetes, with similar rates in males (5.8%) and females (4.9%). The prevalence of diabetes has been continually rising, especially among those aged 75 and older, reaching 18.7%. The most prevalent type is Type 2 diabetes, responsible for 87.6% of cases. Factors like being born overseas, living in underprivileged areas, and having a disability are often linked with higher rates of diabetes. Therefore, the growing occurrence of diabetes is progressing the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

What are the market segments in the sodium glucose cotransporter 2 (sglt2) inhibitors industry?

The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat

2) By Route Of Administration: Oral Route, Other Route Of Administration

3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:

1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana

2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga

4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Who are the dominant players expanding their reach in the sodium glucose cotransporter 2 (sglt2) inhibitors market?

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.

What are the key trends shaping the future of the sodium glucose cotransporter 2 (sglt2) inhibitors market?

Leading companies in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are turning their attention to the development of dual inhibitor treatments for better patient results and blood sugar control. Such therapeutic solutions are designed to target two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) concurrently, thus increasing their effectiveness in handling conditions like heart failure and diabetes. For example, Lexicon Pharmaceuticals Inc., an American biopharmaceutical firm, obtained approval for sotagliflozin, a heart failure treatment, from the Food and Drug Administration (FDA) in May 2023. This unique first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 comes in the form of a daily tablet. It aims to lower cardiovascular death, hospitalizations due to heart failure, and urgent visits for heart failure in adults suffering from heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risks. The drug offers decreased renal glucose and sodium reabsorption, resulting in reduced preload and afterload and lower sympathetic activity.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473

What regions are dominating the sodium glucose cotransporter 2 (sglt2) inhibitors market growth?

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Sodium Benzoate Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/sodium-benzoate-global-market-report

Sodium Lauryl Ether Sulfate [SLES] Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/sodium-lauryl-ether-sulfate-sles-global-market-report

Sodium Cocoyl Isethionate Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/sodium-cocoyl-isethionate-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Growth Rate of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Shape Industry Trends by 2034?

The market size for inhibitors of sodium glucose cotransporter 2 (SGLT2) has experienced significant expansion in recent times. The prediction is that the market will escalate from a worth of $10.17 billion in 2024 to $11.07 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.8%. Factors leading to this growth during the historical period include successful early clinical trials, escalating regulatory approvals, a rise in the diagnosis rate for diabetes, as well as an increased demand for innovative treatments for diabetes.

Anticipated expansion is on the horizon for the sodium glucose cotransporter 2 (SGLT2) inhibitors market, with projections indicating robust growth in the upcoming years. By 2029, the market size is expected to reach $15.4 billion, with a promising compound annual growth rate (CAGR) of 8.6%. Key factors contributing to this growth during the forecast period include an upward trend in diabetes, escalating obesity levels, heightened awareness about diabetes management, and the application of these inhibitors in the treatment of heart and kidney diseases. The forecast period is also set to witness several emerging trends, such as the use of combination therapies, personalized treatment options, advancements in technology, and traditional drug development.

What External and Internal Drivers Are Contributing to the Growth of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market’s Growth?

Expectations for the sodium glucose cotransporter 2 (SGLT2) inhibitor market’s growth are heightened due to the escalating incidence of diabetes. This metabolic disorder, characterized by elevated blood sugar levels, originates from insulin secretion or insulin action defects, or possibly both. Various factors such as urbanization, stress, environmental pollutants, and inadequate access to healthcare incite a rise in diabetes. Diabetes management employs SGLT2 inhibitors to diminish blood glucose levels by flushing glucose out in urine instead of it being reabsorbed by the kidneys. These inhibitors also provide cardiovascular and renal benefits, proving to be critical for controlling diabetes and its associated complications. As reported by the Australian Bureau of Statistics in December 2023, approximately 5.3% or 1.3 million Australians were found to have diabetes in 2022, with similar rates observed in males (5.8%) and females (4.9%). Diabetes rates exhibit an upward trend, notably spiking with increasing age, amounting to 18.7% among those aged 75 or above. The most prevalent form is Type 2 diabetes, contributing to 87.6% of the cases. Other risk factors include being born overseas, living in disadvantaged areas, and having a disability, which contribute to high diabetes rates. This growing incidence of diabetes consequently propels the sodium glucose cotransporter 2 (SGLT2) inhibitor market’s expansion.

Request Your Free Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Who Are the Key Market Players Influencing the Growth of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are:

• Pfizer Inc.

• Johnson & Johnson Inc.

• Merck & Co. Inc.

• Bayer AG

• Sanofi S.A.

What Key Market Trends Are Shaping the Future of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?

Leading firms in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating their efforts on creating dual inhibitor therapeutic formulas. These are tailored to enhance patient results and control blood sugar levels. Dual inhibitor therapies focus on two distinct sodium-glucose cotransporters (SGLT1 and SGLT2) simultaneously to improve effectiveness in handling afflictions like heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., an American biopharmaceutical corporation, got approval from the Food and Drug Administration (FDA) for a medicine for heart failure named sotagliflozin. This pioneering dual inhibitor of sodium-glucose cotransporters 1 and 2 is a daily tablet aimed at lowering cardiovascular mortality, hospital admissions due to heart failure, and urgent heart failure visits in grown-ups dealing with heart failure, type 2 diabetes, chronic kidney disease and other cardiovascular risk factors. It brings about benefits via decreased renal glucose and sodium reabsorption, ultimately lessening preload and afterload and reducing sympathetic activity.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

Which Industry Segments Are Leading the Development and Expansion of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat

2) By Route Of Administration: Oral Route, Other Route Of Administration

3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:

1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana

2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance

3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga

4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

Which Regions Are Emerging as Leaders in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Defines the Scope of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications.

Browse Through More Similar Reports By The Business Research Company:

Sodium Benzoate Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/sodium-benzoate-global-market-report

Sodium Lauryl Ether Sulfate [SLES] Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/sodium-lauryl-ether-sulfate-sles-global-market-report

Sodium Cocoyl Isethionate Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/sodium-cocoyl-isethionate-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: